DUBLIN – Pharmaleads SAS is like the comeback kid who never went away. The French drug developer has spent a decade quietly focused on a novel drug mechanism in pain that was long disregarded by others in the field. The accrual of preclinical and early clinical data on its two lead drug candidates, combined with findings from other labs, have now brought it to the point where the rubber hits the road.